Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study.

IF 1.7 4区医学 Q2 SURGERY

Surgery Today Pub Date : 2025-04-01 Epub Date: 2024-08-27 DOI:10.1007/s00595-024-02930-x

Norifumi Iseda, Shinji Itoh, Takeo Toshima, Shohei Yoshiya, Yuki Bekki, Yuriko Tsutsui, Katsuya Toshida, Shoichi Inokuchi, Toru Utsunomiya, Takahiro Tomino, Keishi Sugimachi, Kazutoyo Morita, Mizuki Ninomiya, Noboru Harada, Ryosuke Minagawa, Tomoharu Yoshizumi

{"title":"Outcome of hepatectomy after systemic therapy for hepatocellular carcinoma: a Japanese multicenter study.","authors":"Norifumi Iseda, Shinji Itoh, Takeo Toshima, Shohei Yoshiya, Yuki Bekki, Yuriko Tsutsui, Katsuya Toshida, Shoichi Inokuchi, Toru Utsunomiya, Takahiro Tomino, Keishi Sugimachi, Kazutoyo Morita, Mizuki Ninomiya, Noboru Harada, Ryosuke Minagawa, Tomoharu Yoshizumi","doi":"10.1007/s00595-024-02930-x","DOIUrl":null,"url":null,"abstract":"Background and purpose: In recent years, new systemic therapies have been developed for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the prognosis of patients with unresectable HCC treated with R0 hepatectomy after systemic therapy.Methods: Data from 27 patients who underwent hepatectomy for HCC after systemic therapy at six facilities were analyzed retrospectively. Cancer-specific survival (CSS) and recurrence-free survival (RFS) after hepatectomy were investigated using Kaplan-Meier curves. We examined the prognostic value of the oncological criteria of resectability for HCC reported by the Japanese Expert Consensus 2023.Results: R0 resection was performed in 24 of the 27 patients. Using the Response Evaluation Criteria in Solid Tumors, 0 patient had a complete response, 16 had a partial response, 6 had stable disease, and 2 had progressive disease. Median CSS was not evaluated, but the median RFS was 17.8 months. Patients with resectable and borderline resectable (BR) 1 cancers had a better prognosis than those with BR2 cancers. The group whose oncological criteria were improved by systemic therapy had a lower recurrence rate than the group whose oncological criteria were maintained, but no difference was observed in CSS.Conclusions: The findings of this study suggest that hepatectomy after systemic therapy may improve the prognosis of HCC patients.","PeriodicalId":22163,"journal":{"name":"Surgery Today","volume":" ","pages":"510-517"},"PeriodicalIF":1.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Surgery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00595-024-02930-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/27 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background and purpose: In recent years, new systemic therapies have been developed for hepatocellular carcinoma (HCC). The aim of this study was to evaluate the prognosis of patients with unresectable HCC treated with R0 hepatectomy after systemic therapy.

Methods: Data from 27 patients who underwent hepatectomy for HCC after systemic therapy at six facilities were analyzed retrospectively. Cancer-specific survival (CSS) and recurrence-free survival (RFS) after hepatectomy were investigated using Kaplan-Meier curves. We examined the prognostic value of the oncological criteria of resectability for HCC reported by the Japanese Expert Consensus 2023.

Results: R0 resection was performed in 24 of the 27 patients. Using the Response Evaluation Criteria in Solid Tumors, 0 patient had a complete response, 16 had a partial response, 6 had stable disease, and 2 had progressive disease. Median CSS was not evaluated, but the median RFS was 17.8 months. Patients with resectable and borderline resectable (BR) 1 cancers had a better prognosis than those with BR2 cancers. The group whose oncological criteria were improved by systemic therapy had a lower recurrence rate than the group whose oncological criteria were maintained, but no difference was observed in CSS.

Conclusions: The findings of this study suggest that hepatectomy after systemic therapy may improve the prognosis of HCC patients.

Abstract Image

查看原文本刊更多论文

肝细胞癌系统治疗后的肝切除术结果：一项日本多中心研究。

背景和目的：近年来，针对肝细胞癌（HCC）开发了新的全身疗法。本研究旨在评估系统治疗后接受 R0 肝切除术的不可切除 HCC 患者的预后：方法：回顾性分析了在六家医疗机构接受系统治疗后接受肝切除术的 27 例 HCC 患者的数据。采用 Kaplan-Meier 曲线研究了肝切除术后的癌症特异性生存率（CSS）和无复发生存率（RFS）。我们研究了日本专家共识 2023 所报告的 HCC 可切除性肿瘤学标准的预后价值：结果：27 例患者中有 24 例实施了 R0 切除术。根据实体瘤反应评估标准，0 例患者完全缓解，16 例患者部分缓解，6 例患者病情稳定，2 例患者病情进展。未评估中位 CSS，但中位 RFS 为 17.8 个月。可切除和边缘可切除（BR）1癌症患者的预后优于BR2癌症患者。通过系统治疗改善了肿瘤标准的一组患者的复发率低于维持肿瘤标准的一组患者，但在CSS方面未观察到差异：本研究结果表明，系统治疗后进行肝切除术可改善 HCC 患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Surgery Today 医学-外科

CiteScore

4.90

自引率

4.00%

发文量

208

审稿时长

1 months

期刊介绍： Surgery Today is the official journal of the Japan Surgical Society. The main purpose of the journal is to provide a place for the publication of high-quality papers documenting recent advances and new developments in all fields of surgery, both clinical and experimental. The journal welcomes original papers, review articles, and short communications, as well as short technical reports("How to do it"). The "How to do it" section will includes short articles on methods or techniques recommended for practical surgery. Papers submitted to the journal are reviewed by an international editorial board. Field of interest: All fields of surgery.